News

Gary Levin Comments on Ruling that Shortens Notice Time for Biosimilar Applicants

News / July 5, 2017

Partner Gary Levin is extensively quoted in two articles published in the June 2017 issue of Specialty Pharmacy News. The article, “Supreme Court Ruling in Sandoz v. Amgen May Speed Up Biosimilars’ Launch Dates” discusses the recent holding that biosimilar applicants need not wait for FDA approval to notify reference drug manufacturers of their intent to market the drugs. Levin told the publication that the decision is key because it “takes away any potential for an extra 180 days of exclusivity” on top of the 12 years that reference biologic sponsors already have. A related article, “Did Biosimilar Company Give Extra Notice of Commercial Marketing?,” looks at the likelihood that biosimilar applicants will give early notice.

Read the article.

Blog

In The Blogs

Previous Next
Data Privacy Monitor
Toying With Children’s Data: Lessons From the FTC’s First Connected Toys Settlement Action
January 17, 2018
Every year, especially around the holidays, more and more products that connect to the internet hit the market. For adults, connected home devices that act like personal domestic assistants have become increasingly popular. Children have...
Read More ->
IP Intelligence: Insight on Intellectual Property
Finjan v. Blue Coat Systems: Attaching Security Profile to a Downloadable Is Patent Eligible
January 16, 2018
In Finjan v. Blue Coat Systems, the Court of Appeals for the Federal Circuit rendered a decision containing interesting rulings on patentable subject matter (affirming the District Court determination that certain claims were patent...
Read More ->
IP Intelligence: Insight on Intellectual Property
Federal Circuit Finds Lanham Act Clause Banning Immoral and Scandalous Trademarks Unconstitutional
January 9, 2018
On December 15, 2017, the Court of Appeals for the Federal Circuit struck down as unconstitutional the clause within 15 U.S.C. § 1052(a) (“Section 2(a)”) banning registration of a trademark that “[c]onsists of or comprises immoral…or...
Read More ->
IP Intelligence: Insight on Intellectual Property
Patent Portfolio Management – a Team Approach to Patent Drafting
January 8, 2018
On my drive to work, there was a trash bag on the freeway, then a box, and later a couple of bags flying around. I wondered where this garbage came from. There were a number of likely candidates: a small pickup truck loaded with...
Read More ->
Data Privacy Monitor
Recent Trends, Future Predictions, and Effective Risk Assessments
January 8, 2018
Risk assessments are a fundamental part of any organization’s risk management process. But many organizations still do not incorporate true risk assessments into their information-security planning, even though doing so makes good business...
Read More ->